Pharmaceutical

AltruBio secures $225m for immune checkpoint programme development

AltruBio has secured $225m in an oversubscribed Series B financing round to propel the clinical development of its ICE programme.

May 23, 2024 - 04:00
AltruBio secures $225m for immune checkpoint programme development
AltruBio has secured $225m in an oversubscribed Series B financing round to propel the clinical development of its ICE programme.
Read the original article

Tags:

Previous Article

Alvotech and Dr Reddy’s partner to commercialise AVT03

Next Article

Endeavor’s IPF Drug Linked to Improved Lung Function in Phase 2 Study

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Selinexor by Karyopharm Therapeutics for Osteosarcoma: ...

Jul 7, 2023

Philips to stop selling sleep apnea machines in U.S. under tentative agreement with FDA, DOJ

Philips to stop selling sleep apnea machines in U.S. un...

Jan 30, 2024

DCGI approves emergency use of Gennova’s Covid-19 booster

DCGI approves emergency use of Gennova’s Covid-19 booster

Jun 21, 2023